@ARTICLE{
author={Weichenthal Michael|,...|,Kandolf Lidija O|,...|,(broj koautora 22)|},
year={2024},
title={Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe},
journal={CANCERS},
volume={16},
number={21},
pages={-},
document_type={Article},
} 

@ARTICLE{
author={Asher Nethanel|,Mohr Peter|,Ellebaek Eva|,Bender Marc|,Mangana Joanna|,Kandolf Lidija O|,Gavrilova Iva|,Ascierto Paolo Antonio|,Gogas Helen|,Rutkowski Piotr|,Schadendorf Dirk|,Bastholt Lars|,Weichenthal Michael|},
year={2024},
title={Length of treatment after partial or complete remission in immunotherapy for metastatic melanoma: An EUMelaReg real world study},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={42},
number={16},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Weichenthal Michael|,...|,Kandolf-Sekulovic Lidija O|,...|,(broj koautora 20)|},
year={2022},
title={Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe},
journal={ANNALS OF ONCOLOGY},
volume={33},
number={7},
pages={S931-S931},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Weichenthal Michael|,...|,Kandolf-Sekulovic Lidija O|,...|,(broj koautora 20)|},
year={2022},
title={EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={40},
number={16},
pages={-},
document_type={Meeting Abstract},
}